CellSource CoTSE:4880 -2.15%69 EV-to-FCF is 4.88 as of Jul. 09, 2026, which is 95% below its 10-year median of 94.01. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 330 Biotechnology companies, CellSource Co ranks better than 66.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CellSource Co's Enterprise Value is 円1,570 Mil.
CellSource Co's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was 円322 Mil. Therefore, CellSource Co's EV-to-FCF for today is 4.88.
The historical rank and industry rank for CellSource Co's EV-to-FCF or its related term are showing as below:
TSE:4880'
s EV-to-FCF Range Over the Past 10 Years
Min: 4.63 Med: 94.01 Max: 419.06
Current: 5.25
During the past 9 years, the highest EV-to-FCF of CellSource Co was 419.06. The lowest was 4.63. And the median was 94.01.
TSE:4880's EV-to-FCF is ranked better than 66.06% of 330
companies
in the Biotechnology industry
Industry Median: 16.33
vs TSE:4880: 5.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellSource Co's PE Ratio (TTM) for today is calculated as:
CellSource Co's share price for today is 円319.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CellSource Co EV-to-FCF Related Terms
CellSource Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CellSource Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, CellSource Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CellSource Co's EV-to-FCF falls into.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was 円322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a EV-to-FCF of 4.88 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CellSource Co and its competitors. This is 95% below median its historical median of 94.01. Over the past decade, CellSource Co's EV-to-FCF has ranged from 4.63 to 419.06. According to the industry distribution chart, CellSource Co ranks #112 out of 330 companies in the Biotechnology industry, placing it in the top 33.9%.
Is CellSource Co's EV-to-FCF too high?
CellSource Co's current EV-to-FCF of 4.88 is 95% below median its 10-year median of 94.01. Over the past 10 years, this metric has ranged from a low of 4.63 to a high of 419.06. The Biotechnology industry median EV-to-FCF is 16.33. CellSource Co's value of 4.88 is 70.1% below this industry median. Based on the distribution chart, CellSource Co ranks #112 out of 330 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #112 out of 330 companies for EV-to-FCF. This puts CellSource Co in the upper half of its industry. The industry median EV-to-FCF is 16.33. CellSource Co's value of 4.88 is 70.1% below this benchmark. Historically, CellSource Co's own EV-to-FCF has ranged from 4.63 to 419.06 over the past decade. While the company's 10-year median is 94.01 vs. the industry median of 16.33, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.33, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current EV-to-FCF of 4.88 is 70.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current EV-to-FCF is 4.88, which is 95% below median its own 10-year median of 94.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current EV-to-FCF is 4.88, which is 95% below median its 10-year median of 94.01 and 70.1% below the Biotechnology industry median of 16.33. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current EV-to-FCF is 4.88 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
EV-to-FCF: 4.88 (95% below median its 10-year median of 94.01)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
Industry Position: 70.1% below the Biotechnology median (#112 of 330)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
